Final Results for the Year Ended 31 December 2018

About this update from Hemogenyx Pharmaceuticals Plc

RNS Number : 4417X Hemogenyx Pharmaceuticals PLC 29 April 2019     Hemogenyx Pharmaceuticals plc ("Hemogenyx" or the "Company")   Final Results for the Year Ended 31 December 2018   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces its Final Results for the year ended 31 December 2018.   All financial amounts are stated in GBP British pounds unless otherwise indicated.   Key highlights ·     Progress continues towards the submission of an Investigational New Drug ("IND") application for a CDX antibody, the Company's lead product candidate   ·     Agreement with global bio-pharmaceutical company to develop the Company's CDX antibodies - potential for licensing deal   ·     Expanding use of CDX antibodies to improve the efficacy of already approved drugs as well as those still in clinical trials for acute myeloid leukemia, and to use as a potential treatment for relapsed/refractory acute myeloid leukemia   ·     Advanced Hematopoietic Chimera ("AHC"), the Company's humanised mouse model, continues to generate interest across the bio-pharmaceutical industry as a platform for disease modelling and drug discovery   ·     Established subsidiary Immugenyx LLC for the development and commercialisation of AHC which is earning collaboration fees for the Company; Immugenyx has received investment from NASDAQ-listed Orgenesis, Inc. ("Orgenesis")   ·     Established Belgium subsidiary, Hemogenyx-Cell SPRL, to focus on Hu-PHEC technology which may be eligible for financial support from the Belgium government; funding secured from Orgenesis   Post-period end highlights ·     Hemogenyx-Cell has lodged an application for a matched funding grant for the further development of Hu-PHEC technology   ·     Reviewed and extended the licence agreement with Cornell University, the patent-holder of the Hu-PHEC technology   ·     Leveraging collaboration with Jannsen Pharmaceuticals, initiating a programme to develop a suite of novel treatments for Systemic Lupus Erythematosus (SLE...

View stock analysis, news, and events for Hemogenyx Pharmaceuticals Plc